BeiGene, Ltd/$ONC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About BeiGene, Ltd

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

Ticker

$ONC
Primary listing

Industry

Biotechnology

Headquarters

Basel, Switzerland

Employees

11,000

ISIN

US07725L1026

BeiGene, Ltd Metrics

BasicAdvanced
$30B
-
-$3.70
0.30
-

Bulls say / Bears say

BeiGene's stock reached a 52-week high of $258.66, reflecting robust revenue growth of 50.22% and a gross profit margin of 83.67%, indicating strong financial health and investor confidence. (Investing.com)
The European Commission approved BeiGene's TEVIMBRA for first-line treatment of advanced esophageal and gastric cancers, potentially expanding the company's market share in oncology. (Business Wire)
Analysts from Morgan Stanley and Jefferies have reiterated 'Buy' ratings for BeiGene, with price targets of $317 and $286 respectively, suggesting strong future performance expectations. (TipRanks)
InvestingPro analysis indicates that BeiGene's stock may be overvalued at current levels, with technical indicators suggesting overbought conditions, which could lead to a price correction. (Investing.com)
A significant increase in short interest for BeiGene's stock suggests that some investors are betting on a decline in the company's share price. (MarketBeat)
Despite recent approvals, BeiGene faces intense competition in the oncology market, which could impact its market share and profitability. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ONC

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs